OMS906

BIOLOGICAL2 trials

Sponsors

Omeros Corporation

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Phase 1

Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria

CompletedNCT05889299

Omeros CorporationParoxysmal Nocturnal Hemoglobinuria

Start: 2022-12-09End: 2025-11-03Updated: 2026-05-11

Phase 2

Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab

CompletedNCT05972967

Omeros CorporationParoxysmal Nocturnal Hemoglobinuria

Start: 2023-03-27End: 2024-10-10Updated: 2025-10-01

Related Papers

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Blood2024-11-053 citations

OMS906, a Novel Alternative Pathway MASP-3 Inhibitor, Normalizes Hemoglobin Levels and Increases Clone Size in Treatment-Naïve PNH Patients

Blood2023-11-025 citations